Related Content
- Big Molecule WatchJuly 25, 2024
FDA Issues Draft Guidance on Demonstrating Biosimilar Interchangeability
- Big Molecule WatchJuly 25, 2024
FDA Approves Samsung’s Eculizumab Biosimilar
- Big Molecule WatchJuly 23, 2024
FTC Issues Interim Report on Ongoing Study of Pharmacy Benefit Managers
- Big Molecule WatchJuly 12, 2024
Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma)
- Big Molecule WatchJuly 9, 2024
Fresenius Announces Launch of Subcutaneous Formulation of TYENNE (tocilizumab-aazg) in the United States
- Big Molecule WatchJuly 9, 2024
FDA Approves Ustekinumab, Aflibercept, and Filgrastim Biosimilars
- Big Molecule WatchJune 28, 2024
Biogen’s TOFIDENCE (tocilizumab) Approved in the EU
- Big Molecule WatchJune 26, 2024
Eculizumab BPCIA Litigation Update: Court Denies Alexion’s Motion for an Injunction Pending Appeal
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics